Back to Results
First PageMeta Content
Genetics / Genetic engineering / Ataluren / Duchenne muscular dystrophy / PTC Therapeutics / Nonsense mutation / Dystrophin / Cystic fibrosis / Health / Biology / Muscular dystrophy


September 17, 2014 PTC Therapeutics Expands Global Presence in Support of Translarna™ Launch in Duchenne Muscular Dystrophy SOUTH PLAINFIELD, N.J., Sept. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT)
Add to Reading List

Document Date: 2014-09-18 03:00:04

Open Document

File Size: 11,87 KB

Share Result on Facebook

City

Dublin / SOUTH PLAINFIELD / /

Company

Gentium SpA / Cystic Fibrosis Foundation Therapeutics Inc. / PTC Therapeutics Inc. / Biogen Idec / EMEA Region / /

Country

Germany / Turkey / France / United States / Italy / United Kingdom / Israel / Spain / Ireland / /

Event

Employment Change / /

Facility

Blood Institute / /

IndustryTerm

supply chain / biopharmaceutical / proprietary technologies / manufacturing / therapies for rare disorders / /

MedicalCondition

muscular dystrophy / disease / Parent Project Muscular Dystrophy / excellent rare disease / rare disorders / disorder / infectious diseases / genetic disorders / /

Organization

European Medicines Agency / Muscular Dystrophy Association / Cystic Fibrosis Foundation / European Union / National Center for Research Resources / National Heart / Lung / and Blood Institute / FDA's office of Orphan Products Development / /

Person

Adrian Haigh / Mark Rothera / /

Position

Vice President & General Manager / Regional Vice President / Commercial Operations / Senior Vice President / Commercial Operations / Chief Commercial Officer / /

Product

Translarna / /

ProvinceOrState

New Jersey / /

Technology

drug discovery / genetic code / /

URL

www.ptcbio.com / /

SocialTag